Xenopat is a leading brand in the field of preclinical services and personalized cancer treatment. Their mission is to utilize the latest scientific findings in the fight against cancer. Xenopat offers a range of advanced preclinical services to assist researchers and companies dedicated to developing new anticancer drugs.

With their OrthoXenoBank®, researchers have access to orthotopic models of various tumor types, characterized at both histological and genetic levels, and with different sensitivity to different chemotherapies. This cutting-edge tool allows for the most innovative approaches to drug development. In addition, Xenopat provides personalized cancer treatment options, utilizing state-of-the-art technology to help healthcare professionals and patients select the best therapy for each individual.

By generating an orthoxenograft® from a small fragment of the patient's tumor, Xenopat can test multiple drugs and determine the most effective treatment. With a team comprised of experts from the Catalan Institute of Oncology, the Bellvitge Biomedical Research Institute, and the Bellvitge University Hospital, Xenopat is at the forefront of cancer research and treatment